Sector Update: Healthcare Stocks Lean Lower Pre-Bell Wednesday

MT Newswires Live

Yesterday

Healthcare stocks were leaning lower pre-bell Wednesday, with the State Street Health Care Select Sector SPDR ETF (XLV) down 0.1% and the iShares Biotechnology ETF (IBB) declining by 0.5%.

Boston Scientific (BSX) has identified a cybersecurity incident that affected its certain IT systems and led to global disruption in operations, the company said in a filing. Boston Scientific shares were down more than 5% premarket.

Jazz Pharmaceuticals' (JAZZ) wholly owned subsidiary plans to offer $1 billion of exchangeable senior notes due 2032, the company said. Jazz Pharmaceuticals stock was down more than 2% pre-bell.

Summit Therapeutics (SMMT) partner Akeso reported "positive" results from a phase 3 trial of ivonescimab plus chemotherapy, compared with durvalumab plus chemotherapy as a first-line treatment of advanced biliary tract cancer. Shares of Summit Therapeutics were up more than 12% premarket.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"Tiger Brokers,U.S. stock trading,Hong Kong stock trading,trading U.S. stocks,stock information,stock prices,U.S. stock quotes,U.S. stock trading,Hong Kong stock trading,IPO trading,buying U.S. stocks,global investment","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://nz.tigermarketb.com/news/2662712851"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2662712851\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2662712851?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-26 21:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2662712851","market":"sh","top_or_hot":-1,"title":"Sector Update: Healthcare Stocks Lean Lower Pre-Bell Wednesday","media":"MT Newswires Live","content":"<html><body><p> Healthcare stocks were leaning lower pre-bell Wednesday, with the State Street Health Care Select Sector SPDR ETF (XLV) down 0.1% and the <a href=\"https://laohu8.com/S/EEMA\">iShares</a> Biotechnology ETF (IBB) declining by 0.5%.</p><p>Boston Scientific (BSX) has identified a cybersecurity incident that affected its certain IT systems and led to global disruption in operations, the company said in a filing. Boston Scientific shares were down more than 5% premarket.</p><p>Jazz Pharmaceuticals' (JAZZ) wholly owned subsidiary plans to offer $1 billion of exchangeable senior notes due 2032, the company said. Jazz Pharmaceuticals stock was down more than 2% pre-bell.</p><p><a href=\"https://laohu8.com/S/SMMT\">Summit</a> <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (SMMT) partner Akeso reported \"positive\" results from a phase 3 trial of ivonescimab plus chemotherapy, compared with durvalumab plus chemotherapy as a first-line treatment of advanced biliary tract cancer. Shares of Summit Therapeutics were up more than 12% premarket.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sector Update: Healthcare Stocks Lean Lower Pre-Bell Wednesday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSector Update: Healthcare Stocks Lean Lower Pre-Bell Wednesday\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-08-26 21:18</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Healthcare stocks were leaning lower pre-bell Wednesday, with the State Street Health Care Select Sector SPDR ETF (XLV) down 0.1% and the <a href=\"https://laohu8.com/S/EEMA\">iShares</a> Biotechnology ETF (IBB) declining by 0.5%.</p><p>Boston Scientific (BSX) has identified a cybersecurity incident that affected its certain IT systems and led to global disruption in operations, the company said in a filing. Boston Scientific shares were down more than 5% premarket.</p><p>Jazz Pharmaceuticals' (JAZZ) wholly owned subsidiary plans to offer $1 billion of exchangeable senior notes due 2032, the company said. Jazz Pharmaceuticals stock was down more than 2% pre-bell.</p><p><a href=\"https://laohu8.com/S/SMMT\">Summit</a> <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (SMMT) partner Akeso reported \"positive\" results from a phase 3 trial of ivonescimab plus chemotherapy, compared with durvalumab plus chemotherapy as a first-line treatment of advanced biliary tract cancer. Shares of Summit Therapeutics were up more than 12% premarket.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2244417387.USD","symbol_name":"FIDELITY SUSTAINABLE US EQUITY \"A\" (USD) ACC","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2662712851","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2662712851","pubTimestamp":1787750291,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Healthcare stocks were leaning lower pre-bell Wednesday, with the State Street Health Care Select Sector SPDR ETF  down 0.1% and the iShares Biotechnology ETF  declining by 0.5%.Boston Scientific  has identified a cybersecurity incident that affected its certain IT systems and led to global disruption in operations, the company said in a filing. Boston Scientific shares were down more than 5% premarket.Jazz Pharmaceuticals'  wholly owned subsidiary plans to offer $1 billion of exchangeable senior notes due 2032, the company said. Jazz Pharmaceuticals stock was down more than 2% pre-bell.Summit Therapeutics  partner Akeso reported \"positive\" results from a phase 3 trial of ivonescimab plus chemotherapy, compared with durvalumab plus chemotherapy as a first-line treatment of advanced biliary tract cancer. Shares of Summit Therapeutics were up more than 12% premarket.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2244417387.USD":"FIDELITY SUSTAINABLE US EQUITY \"A\" (USD) ACC","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU2362541513.USD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (USD) ACC","BSX":"波士顿科学","LU0225283273.USD":"SCHRODER ISF GLOBAL EQUITY ALPHA \"A\" (USD) ACC","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","LU1153585028.USD":"BGF GLOBAL LONG-HORIZON EQUITY  \"A4\" (USD) INC","LU0077335932.USD":"FIDELITY AMERICAN GROWTH \"A\" INC","BK4581":"高盛持仓","LU1989771016.USD":"东方汇理环球老龄化投资基金 A2 Acc","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","LU0029874061.USD":"TEMPLETON GLOBAL SMALLER COMPANIES \"A\" YDIS INC","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","HCSG":"Healthcare Svcs Group Inc","LU0950375773.USD":"BNP PARIBAS SUSTAINABLE GLOBAL LOW VOL EQUITY \"C\" (USD) INC A","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU0187121727.USD":"FIDELITY SUSTAINABLE US EQUITY \"A\" (USD) INC","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","IBB":"生物科技指数ETF-iShares Nasdaq","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","SMMT":"Summit Therapeutics PLC","LU0266013472.USD":"AXA WF - Framlington Longevity Economy A Cap USD","IE00BN0W2W23.USD":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (USD) ACC","XLV":"健康照护类股ETF-SPDR","LU1989772923.USD":"CPR Invest - Climate Action A2 Acc USD-H","BK7095":"多种金属与采矿","LU1989764664.SGD":"CPR Invest - Global Disruptive Opportunities A2 Acc SGD-H","JAZZ":"爵士制药","LU1791710400.SGD":"Fidelity Global Demographics A-ACC-SGD","LU0528227936.USD":"富达环球人口趋势基金A-ACC","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","LU0823417653.USD":"BNP PARIBAS SUSTAINABLE GLOBAL LOW VOL EQUITY \"C\" (USD) ACC","BK4082":"医疗保健设备","LU2362541273.HKD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (HKD) ACC","LU2506951875.HKD":"BNP PARIBAS SUSTAINABLE GLOBAL LOW VOL EQUITY \"CRH\" (HKDHDG) ACC","LU0128526141.USD":"TEMPLETON GLOBAL SMALLER COMPANIES \"A\" ACC","LU0238689110.USD":"贝莱德环球动力股票基金","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","BK4504":"桥水持仓","LU2357305700.SGD":"Allianz Global Artificial Intelligence ET H2-SGD","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","BSX.AU":"BLACKSTONE MINERALS LTD","LABU":"三倍做多标普生物-Direxion","LU2491049909.HKD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (HKD) ACC","LU0011850046.USD":"贝莱德全球长线股票 A2 USD","LU2491050154.USD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (USD) ACC","XBI":"SPDR S&P Biotech ETF","IE00BN0W2T93.GBP":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (GBP) ACC","LU0345769631.USD":"NINETY ONE GSF GLOBAL EQUITY \"A\" (USD) INC"},"translate_title":"行业更新：医疗保健股周三走低盘前","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IBB":1,"XBI":0.6,"JAZZ":1,"BSX":1,"LABU":0.6,"HCSG":1.5,"BSX.AU":1,"SMMT":1,"XLV":1.5},"content_text":"Healthcare stocks were leaning lower pre-bell Wednesday, with the State Street Health Care Select Sector SPDR ETF (XLV) down 0.1% and the iShares Biotechnology ETF (IBB) declining by 0.5%.Boston Scientific (BSX) has identified a cybersecurity incident that affected its certain IT systems and led to global disruption in operations, the company said in a filing. Boston Scientific shares were down more than 5% premarket.Jazz Pharmaceuticals' (JAZZ) wholly owned subsidiary plans to offer $1 billion of exchangeable senior notes due 2032, the company said. Jazz Pharmaceuticals stock was down more than 2% pre-bell.Summit Therapeutics (SMMT) partner Akeso reported \"positive\" results from a phase 3 trial of ivonescimab plus chemotherapy, compared with durvalumab plus chemotherapy as a first-line treatment of advanced biliary tract cancer. Shares of Summit Therapeutics were up more than 12% premarket.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}